Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia
Leukemia · 2025
DOI: 10.1038/s41375-024-02493-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Leukemia, 2025. Verfasst von Tommaso Balestra und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Receptors, Cytokine, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Down Syndrome, Philadelphia Chromosome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Defense (United States Department of Defense), U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI), U.S. Department of Health & Human Services | National Institutes of Health (NIH).
Abstract (Originalsprache)
CRLF2 rearrangements occur in >50% of Ph-like and Down syndrome (DS)-associated B-acute lymphoblastic leukemia (ALL) and induce constitutive kinase signaling targetable by the JAK1/2 inhibitor ruxolitinib under current clinical investigation. While chimeric antigen receptor T cell (CART) immunotherapies have achieved remarkable remission rates in children with relapsed/refractory B-ALL, ~50% of CD19CART-treated patients relapse again, many with CD19 antigen loss. We previously reported preclinical activity of thymic stromal lymphopoietin receptor-targeted cellular immunotherapy (TSLPRCART) against CRLF2 -overexpressing ALL as an alternative approach. In this study, we posited that combinatorial TSLPRCART and ruxolitinib would have superior activity and first validated potent TSLPRCART-induced inhibition of leukemia proliferation in vitro in CRLF2- rearranged ALL cell lines and in vivo in Ph-like and DS-ALL patient-derived xenograft (PDX) models. However, simultaneous TSLPRCART/ruxolitinib or CD19CART/ruxolitinib treatment during initial CART expansion diminished T cell proliferation, blunted cytokine production, and/or facilitated leukemia relapse, which was abrogated by time-sequenced/delayed ruxolitinib co-exposure. Importantly, ruxolitinib co-administration prevented fatal TSLPRCART cytokine-associated toxicity in ALL PDX mice. Upon ruxolitinib withdrawal, TSLPRCART functionality recovered in vivo with clearance of subsequent ALL rechallenge. These translational studies demonstrate an effective two-pronged therapeutic strategy that mitigates acute CART-induced hyperinflammation and provides potential anti-leukemia ‘maintenance’ relapse prevention for CRLF2 -rearranged Ph-like and DS-ALL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
- Department of Pediatrics, University of Pennsylvania, School of Medicine, Philadelphia, PA, USA.
- Division of Hematology/Oncology/Bone Marrow Transplant and Center for Cancer and Blood Disorders, Children's Hospital of Colorado, Aurora, CO, USA.
- Texas Children's Hospital Cancer Center and Division of Pediatric Hematology/Oncology, Houston, TX, USA.
- Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
- University of Colorado Anschutz Medical Campus and Gates Institute, Aurora, CO, USA.
ORCID-Profile: Tommaso Balestra, Lisa M Niswander, Jacob J Junco, Karen R Rabin, Terry J Fry, Sarah K Tasian
Förderung
- U.S. Department of Defense (United States Department of Defense)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
- U.S. Department of Health & Human Services | National Institutes of Health (NIH)
Zitieren
APA
Balestra, T., Niswander, L. M., Bagashev, A., Loftus, J. P., Ross, S. L., Chen, R. K., McClellan, S. M., Junco, J. J., Bárcenas López, D. A., Rabin, K. R., Fry, T. J., & Tasian, S. K. (2025). Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia. Leukemia. https://doi.org/10.1038/s41375-024-02493-3
Vancouver
Balestra T, Niswander LM, Bagashev A, Loftus JP, Ross SL, Chen RK, et al. Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia. Leukemia. 2025. doi:10.1038/s41375-024-02493-3
BibTeX
@article{Balestra2025,
author = {Balestra, Tommaso and Niswander, Lisa M and Bagashev, Asen and Loftus, Joseph P and Ross, Savannah L and Chen, Robert K and McClellan, Samantha M and Junco, Jacob J and Bárcenas López, Diego A and Rabin, Karen R and Fry, Terry J and Tasian, Sarah K},
title = {Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia},
journal = {Leukemia},
year = {2025},
doi = {10.1038/s41375-024-02493-3}
}
EUVIMED